Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Lindbrook Capital LLC

Lindbrook Capital LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 369 shares of the biopharmaceutical company’s stock after buying an additional 100 shares during the quarter. Lindbrook Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $71,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. U.S. Capital Wealth Advisors LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at $10,892,000. Harbor Capital Advisors Inc. lifted its holdings in Alnylam Pharmaceuticals by 6.0% in the third quarter. Harbor Capital Advisors Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 163 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Alnylam Pharmaceuticals by 9.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 363 shares during the last quarter. Xponance Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 3rd quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock worth $2,654,000 after buying an additional 109 shares during the last quarter. Finally, Raymond James & Associates raised its stake in shares of Alnylam Pharmaceuticals by 5.1% during the 3rd quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock worth $2,198,000 after buying an additional 598 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ALNY. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 13th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. HC Wainwright reaffirmed a “buy” rating and set a $395.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Nine analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $143.80 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $143.50 and a 12 month high of $218.88. The company has a 50-day moving average of $150.77 and a 200-day moving average of $166.28. The company has a market cap of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. During the same period in the prior year, the company earned ($1.68) EPS. The company’s revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.